Author Archives: admin


SHE Initiative Shines Light on Gender Disparities in Oncology Workforce – Targeted Oncology

The Association of Community Cancer Centers (ACCC) National Oncology Conference each year helps community oncologists approach both unique and typical challenges with innovative strategies. This year, one of the challenges addressed that has been increasingly raised throughout the year was the topic of disparities in the medical field.

To close out the ACCC 37th (Virtual) National Oncology Conference, keynote speaker Nick Smith-Stanley, MBA, addressed the topic of diversity and inclusion for women in medicine, and specifically in the field of oncology.

Smith-Stanley, associate director of finance and administration, Livestrong Cancer Institutes, Dell Medical School, associate director of administration and strategic planning, Department of Oncology, Dell Medical School, The University of Texas at Austin, explained the challenges faced by women in the oncology workplace and quantified the divide seen between the number of men and women in oncology and in positions of leadership in the medical field.

By discussing the lack of women in the field of oncology, he said, it will hopefully lead to developing strategies that address such challenges, which can then lead to real change.

He also presented how the Livestrong Cancer Institutes Dell Medical School has created a program that seeks to address this gap and give the future generation of women in medicine the tools they need to succeed.

The Growing Gender Divide Across a Medical Career Span

Oncology is known to be a male-dominated field in the healthcare space. Although the number of female students and physicians in the field has grown over the past few years, the proportion of women compared to men in medicine is still less than half. Further, the numbers get lower throughout the continuum of a medical career from medical student to physician to professor and then dean.

Smith-Stanley said that, encouragingly, for the first time in history, the number of female medical students is higher than the number of male students, but the difference is marginal. The rates decrease, however, over the course of a medical career. The number of female residents and fellows is below 50% and has not changed much in the last 10 years, and specific to oncology and hematology, the proportion of female residents and fellows is below about 45%.

Among practicing physicians, only 35% are female, and within the oncology/hematology field specifically, the rate is closer to one-third. However, this is increased from 10 years ago when the rate of female physicians was only about 28% overall and about 25% in the oncology field.

Within research in general, as of 2018, 50% of STEM (science, technology, engineering, and mathematics) positions were held by women, but specifically to science and engineering, only 28% of women hold positions in these fields.

Across all disciplines in science and oncology, we see women struggling to be considered for opportunities for promotion and leadership, Smith-Stanley said. One faculty member at Dell Medical School told us that throughout her career she has seen male colleagues with fewer accomplishments get promoted at the same time. In addition, she shared that at previous institutions, rules were not as rigid for promotion and tenure for men as they were for women, they were willing to bend the rules for men, but not for women. This shows that this is not only a personal or organizational issue, it is by far a systemic issue.

He pointed out that as a result, women hold fewer positions of leadership than men. Only 19% of department chairs were held by women in the year 2019 and only 21% of full professors are female.

This poses a greater problembecause of the lack of mentorship opportunities. If our students and junior faculty are unable to identify women in positions of leadership and mentorship to help guide their career then they are less likely to progress in their career as well, he commented.

He suggested that these rates reduce across the span of a medical career due to a lack of tools, mentorship, and support given to women in medicine.

Smith-Stanley offered some strategies to bridge the gender divide through organizational changes. Starting with culture, organizational leaders must embrace and promote an all-inclusive environment. Training on diversity and bias is one way to overcome these barriers and allow for change. Providing opportunities for professional development, including mentorship and networking, can also help to retain the women in the medical workforce.

Livestrong Cancer Institutes, he said, is one of the few cancer centers across the country that is led by a woman, S. Gail Eckhardt, MD, who is the director and associate dean of cancer programs at the company. As such, Dell Medical School is focused on addressing such healthcare disparities and leaders at the Livestrong Cancer Institutes feel that they have a responsibility to address the role that women play in cancer, research, and academics.

SHE Takes a Step Towards Overcoming Gender Disparities

The Livestrong Cancer Institute stressed the use of early education and mentorship to bridge the gender gap, which ultimately led to the development of the Summer Healthcare Experience (SHE) program in oncology. SHE is a free, immersive week-long program for introducing female-identifying high school juniors and seniors to a range of career opportunities in the cancer field. The program was launched in the summer of 2019 when 8 young women from Austin were selected with health program teachers and brought to the Dell Medical School to learn more about the various careers involved with cancer care.

The SHE program sought to empower young women to take control of their education and future careers by giving them tools to overcome challenges in the workplace. The high school students were given the opportunity to participate in research and interact with the clinical teams. Participating students also came away with a general knowledge of cancer, how it is treated, and the challenges that patients with cancer and their caregivers face. Additionally, the program promoted leadership skills and professionalism that could be used throughout their career, no matter the field.

During the week, the students worked with women in the cancer center to learn about cancer anatomy and how physicians work together for the care of patients with cancer. In the wet research lab, the students were able to see cell cultures and tumor slides and they also investigated different brain tumors in the neuro-oncology lab. The students were also able to join in on the molecular tumor boards to see the interaction between various departments for deciding on optimal care for a patient. In a survivorship session, the students were also able to meet with cancer survivors and their families and learn about their cancer journeys. Additionally, the students learned about health services research in the community and how health services researchers are investigating healthcare disparities in patients with cancer.

Throughout the week, the students were able to interact with female leaders from the cancer center, including center director Eckhardt, to hear about and learn from their experiences and the challenges they faced in their careers. They also met with a number of community organizations, from American Cancer Society to the Austin Center for Grief and Loss, to hear about how these organizations are assisting patients with cancer in the city.

Its not enough to just talk about equity and inclusion. You need to have people who are invested in the conversation and the desire to make a difference. Thats exactly what we saw in the first year of SHE, Smith-Stanley said.

The students were tasked with coming up with a comprehensive care plan for a cancer case based on all they learned during the week. These plans were then presented at the end of the week to faculty from Livestrong Cancer Institutes, Dell Medical Center, the students high school teachers, and their families.

We could not have been more thrilled with the results. They were confident, they were thoughtful, they were knowledgeable, they were compassionate. The transformation that we witnessed from Monday to Friday was remarkable, Smith-Stanley commented.

Moving forward, the Livestrong Cancer Institutes hopes to expand the SHE program to more students and extend the program to 2 weeks. The program also hopes to add in more biomedical research, entrepreneurship education, a college prep day, and even a post-program internship. Livestrong Cancer Institutes is also partnering with other organizations to spread the SHE program to 4 other cancer centers, and hopefully nationwide, although this expansion has been delayed by the coronavirus disease 2019.

Reference

Smith-Stanley N. Addressing the Disparities of Women in Oncology. Presented at: ACCC National Oncology Conference; September 14-18, 2020; Virtual.

Read more:
SHE Initiative Shines Light on Gender Disparities in Oncology Workforce - Targeted Oncology

Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis – The Daily Chronicle

Roots Analysis has announced the addition of Cell Therapy Manufacturing Market (2nd Edition), 2018-2030 report to its list of offerings.

Natasha Thakur, the principal analyst, stated, The growing number of cell therapy candidates continues to create an increasing demand for facilities that offer manufacturing services for these complex pharmacological interventions. Presently, over 145 companies / organizations are actively offering manufacturing services for such products. The installed global manufacturing capacity is estimated to be over 1 billion sq ft, with the maximum capacity available in North America

The report presents opinions on several key aspects of the market. Among other elements, it includes:

The report features inputs from a number of eminent industry stakeholders. Thakur remarked, Most of the experts we spoke to confirmed that the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with setting-up such facilities. The report features detailed transcripts of discussions held with the following experts:

The research also includes detailed profiles of the following players:

For additional details, please visithttps://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing-market-2nd-edition-2018-2030/209.hl or email [emailprotected]

Contact:

Gaurav Chaudhary

+1-604-595-4954

See more here:
Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - The Daily Chronicle

Large-scale RNAi screening uncovers therapeutic targets in the parasite Schistosoma mansoni – Science Magazine

Schistosome biology illuminated

Schistosomiasis is caused by a parasitic flatworm about which little is known. Therefore, options to combat human disease caused by schistosome infection are limited. To aid in our quest to develop treatments, two studies undertook molecular investigations of the parasite Schistosoma mansoni. By generating a single-cell atlas, Wendt et al. identified the developmental trajectory of the flatworm, including the blood-feeding gut required for its survival in the host. From these data, they found a gene required for gut development that, when knocked out through RNA interference, confers reduced pathology in infected mice. Wang et al. performed a large-scale RNA interference survey of S. mansoni and identified an essential pair of protein kinases that can be targeted by approved pharmacological intervention (see the Perspective by Anderson and Duraisingh). These molecular investigations add to our understanding of the schistosome parasite and provide biological information that may help to combat this neglected tropical disease.

Science, this issue p. 1644, p. 1649; see also p. 1562

Schistosome parasites kill 250,000 people every year. Treatment of schistosomiasis relies on the drug praziquantel. Unfortunately, a scarcity of molecular tools has hindered the discovery of new drug targets. Here, we describe a large-scale RNA interference (RNAi) screen in adult Schistosoma mansoni that examined the function of 2216 genes. We identified 261 genes with phenotypes affecting neuromuscular function, tissue integrity, stem cell maintenance, and parasite survival. Leveraging these data, we prioritized compounds with activity against the parasites and uncovered a pair of protein kinases (TAO and STK25) that cooperate to maintain muscle-specific messenger RNA transcription. Loss of either of these kinases results in paralysis and worm death in a mammalian host. These studies may help expedite therapeutic development and invigorate studies of these neglected parasites.

View post:
Large-scale RNAi screening uncovers therapeutic targets in the parasite Schistosoma mansoni - Science Magazine

Human Embryonic Stem Cells Market – Growth, Trends, and Forecast (2020 – 2025) – GlobeNewswire

September 23, 2020 15:03 ET | Source: ReportLinker

New York, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Human Embryonic Stem Cells Market - Growth, Trends, and Forecast (2020 - 2025)" - https://www.reportlinker.com/p05974111/?utm_source=GNW In the United States, two major government agencies, National Institutes of Health (NIH) and California Institute of Regenerative Medicine (CIRM), fund almost all the translational researches and regenerative medicine development in the country. It is estimated that the United States government invests around USD 800-900 million every year in stem cell research. Additionally, other factors such as the high prevalence of cardiac and malignant diseases, and rising demand for regenerative medicines are expected to drive the market.

Key Market Trends Stem Cell Biology Research Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing. Stem cell biology research will show better growth, owing to the high prevalence of cardiac and malignant diseases. An article published by the ISSCR (International Society for Stem Cell Research) reported that the stem cells hold potential for the treatment of Parkinsons disease in humans. Recently, one of the market players, International Stem Cell Corporation (ISCO), received the patent covering methods for generating HLA homozygous parthenogenetic human stem cell lines from unfertilized eggs. The patent was issued in Australia. Furthermore, to boost the pace of stem cell research, the government is providing funding opportunities to researchers. Thus, owing to these factors, the market studied is expected to witness a high growth rate over the forecast period.

North America Dominates the Human Embryonic Stem Cells Market

The human embryonic stem cells market is expected to dominate in the North America region owing to extensive research activities, along with high burden of chronic diseases and genetic disorders in the region. The United States also shows a high incidence of other diseases, such as diabetes, heart disease, renal failure, and osteoporosis. Human embryonic stem cells have high potential for use in treatment and may become a standard of care for these diseases. Additionally, the FDA has approved clinical trials, which indicated the use of stem cells. Hence, these factors are expected to influence the growth of the human embryonic stem cells market over the forecast period.

Competitive Landscape The global players into the human embryonic stem cells market are Astellas Pharma Inc, PeproTech Inc, Lineage Cell Therapeutics Inc, Merck KGaA, PromoCell GmbH, STEMCELL Technologies Inc, Thermo Fisher Scientific and ViaCyte, Inc.

Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format - 3 months of analyst support Read the full report: https://www.reportlinker.com/p05974111/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Lyon, FRANCE

Formats available:

See more here:
Human Embryonic Stem Cells Market - Growth, Trends, and Forecast (2020 - 2025) - GlobeNewswire

Search in east London to find stem cell donors – East London Advertiser

PUBLISHED: 10:00 18 September 2020 | UPDATED: 14:44 21 September 2020

Mike Brooke

Research into stem cell cancer at Queen Mary University's Whitechapel campus. Picture: Jorge Duarte Estevao

Jorge Duarte Estevao

Email this article to a friend

To send a link to this page you must be logged in.

Donors are desperately needed to combat the impending influx of new blood cancer cases following a delay in diagnoses caused by the Coronavirus lockdown.

Now the international DKMS blood cancer charity known as We Delete Blood Cancer is running a blood cancer awareness month to try and fill the gap in donor registrations.

The need for transplants is even more urgent now than before lockdown, a charity spokesman said.

The gap in finding donors is worrying as its even more important to offer hope during the Coronavirus outbreak to people with devastating blood cancers, whose lives have also been harmed by the pandemic. A transplant is their last hope of staying alive.

Donor Sam Schmidt in Limehouse underwent a life-giving transplant during lockdown to donate stem cells after being successfully matched with a patient from a worldwide search.

The 25-year-old accounts manager registered with the charity when he moved into Narrow Street from west London after being inspired by Peter McCleaves story, a father of two young boys found to have blood cancer after being fit and running the Ironman triathlon.

Its quick and easy to sign-up to the stem cell blood cancer register, Sam explained. You just take a cotton swab of your mouth and send it off in the post.

The process isnt that bad, like giving blood. I just lay down and binge watched TV for a few hours, but knowing I was potentially saving someones life.

The search for donors continues amid widespread confusion about what is involved, which holds many volunteers back, the charity says.

Among the biggest misconceptions is thinking the process is invasive, difficult, painful or involving a needle in the spine.

But nine-out-of-10 donations in reality are made with blood taken from one arm into a machine that extracts the stem cells before being put back through the other arm, usually taking four to six hours.

Its incredible knowing you could be someones only hope of survival, Sam tells you. Covid-19 doesnt stop other people needing your help.

Sam unfortunately was no match for Peter McCleave, the patient who had inspired him to sign up.

Peter has been given just seven years to live, yet still hopes to find his matching donor.

Yet he has encouraged through his public speaking events people like Sam in Limehouse to register online.

If you value what this story gives you, please consider supporting the East London Advertiser. Click the link in the orange box above for details.

See the article here:
Search in east London to find stem cell donors - East London Advertiser

Napa County Taxpayers Association offers election recommendations | Letters to the Editor – Napa Valley Register

The Napa County Taxpayers Association provides the following recommendations for the November 3, 2020 election:

-- Doris Gentry for Mayor of the city of Napa.

-- Bernie Narvaez for City Council in Area 4.

-- James Hinton for City Council in area 2

Proposition Recommendations:

Vote No on Proposition 14: In 2004, voters approved $3 billon for a publicly funded stem cell agency - CIRM. CIRM has been criticized for insider dealing and inefficiency. Proposition 14 seeks another $5.5 billion, while failing to address issues of accountability. This will cost $2.3 billion in interest payments alone, taking $260 million out of the state budget yearly for 30 years. Stem cell research has been, and is, being funded by the federal government and private enterprise.

Vote No on Proposition 15: Innocuous labeling of purpose as, "for Schools and Communities" does not stress the fact that this proposition is intended to increase the taxes for all businesses and industrial activities. It does this by removing the protections which have been provided by Proposition 13. The higher property taxes, which will result in higher rents, will be passed onto the consumer, becoming a tax on all of us -i.e. "We the People."

Read this article:
Napa County Taxpayers Association offers election recommendations | Letters to the Editor - Napa Valley Register

Investments in Innovation to Drive the Animal stem cell therapy Market between 2017 and 2025 – Industry Today

Animal stem cell therapy is a usage of animals stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease.

Animal stem cell therapy is a usage of animals stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease. The animal stem cell therapy process involve three steps which include collection of stem cell sample from animals and preparing the sample to concentrate the stem cells. Finally, the therapy includes transferring the stem cells into the injured site for treatment. Animal stem cell therapy increases the expectancy of life in animals with no side effects. It is available for the treatment of arthritis, degenerative joint disorders, tendon, and ligaments injuries in animals. Stem cell therapy is most often used to treat dogs, cats, and horses. But recent developments made it possible to use animal stem cell therapy in tiger, pig, etc. Present animal stem cell therapy is studied in treatments of the inflammatory bowel, kidney, liver, heart and immune-mediated diseases respectively.

Animal Stem Cell Therapy Market: Drivers and Restraints

Increasing prevalence of disease in animals with growing population and to increase the animals quality of life, the companies focus shifting towards animal stem cell therapies. Along with increasing government funding for the protection of animals and fast approvals of FDA contributing towards the rapid growth of the animal stem cell therapy. The research in animal stem cells offers great promise for understanding underlying mechanisms of animal development; it gives great opportunities to treat a broad range of diseases and conditions in animals. Animal stem cell therapy is increasingly recognized as critical translational models of human disease for treatment. All these factors act as drivers for the robust growth of the animal stem cell therapy market.

To remain ahead of your competitors, request for a samplehere@

https://www.persistencemarketresearch.com/samples/14941

Animal Stem Cell Therapy Market: Segmentation

Segmentation based on Applications

Segmentation based on End-user

Animal Stem Cell Therapy Market: Market Overview

Studies in the animal stem cell therapy continue at a breathtaking pace due to increasing demand and treatment cost covered in reimbursements. And animal stem cell therapy is more effective than traditional treatment available in the market which is boosting the companies to increase the spending in the R&D for innovative methods. Because of the novelty and complexity of animal stem cell therapy, FDA encourages individuals, universities and drug companies for further innovations. The future expected with double CAGR during the forecasted period.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/14941

Animal Stem Cell Therapy Market: Region-wise Overview

Regarding geographies, North America is dominating the global animal stem cell therapy market due to the increased incidence rate and awareness about the therapy. U.S represents the largest market share in the North America due to the increasing demand for the therapy. Europe and Asia-Pacific are showing a significant growth rate during the forecasted period due to the growing adoption of the animal stem cell therapy. The animal stem cell therapy market in underdeveloped countries is slow when compared to the developed countries.

Animal Stem Cell Therapy Market: Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/14941

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg Persistence Market Research Address 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Salessales@persistencemarketresearch.com Websitehttps://www.persistencemarketresearch.com

See the original post here:
Investments in Innovation to Drive the Animal stem cell therapy Market between 2017 and 2025 - Industry Today

Fred Hutch Evergreen Fund awards six grants to promising projects – Fred Hutch News Service

Six Fred Hutchinson Cancer Research Center teams have been selected as this years recipients of grants from the Evergreen Fund, which supports early research projects thought to have enough commercial potential to attract future business partners.

Since 2017, the donor-supported Evergreen Fund has awarded over $4 million to projects proposed by scientists seeking a well-timed financial boost to translate their ideas into lifesaving advances for patients.

Despite the disruption of COVID-19, the Evergreen Fund once again offers our researchers the opportunity to complete the critical experiments that venture capital and pharma partners expect to see when evaluating a partnership opportunity, said Hilary Hehman, the Hutchs associate vice president of Strategic Partnerships & Alliances.

The Hutch program also provides researchers feedback on their research, funded or not, from a group of seasoned investors who evaluated their proposals.

This year, the Evergreen Fund distributed three pilot grants of $50,000 each that are designed to give big and bold ideas with commercial application an infusion of funds to demonstrate the projects potential within a six-month period. Another trio of projects were awarded $200,000 each to accelerate their research over a two-year period. The goal of these larger, so-called Beyond Pilot grants is to help researchers whose ideas are further along. These scientists have shown promising data and a commercial path forward, but their projects need more development to attract external financial support.

Drs. Kristin Anderson and Lucas Sullivan received a Beyond Pilot grant for their project to boost the viability of T cells engineered to destroy pancreatic tumors, malignancies stubbornly resistant to therapies. Andersons T cells, designed with receptors that zero in on specific molecular markers on the pancreatic tumor cell surface, have shown promise in preclinical studies.

Yet these living drugs cannot survive for long in the toxic microenvironment of pancreatic tumors. The team is experimenting with new approach they call metabolic reprogramming, which involves a second bit of T-cell engineering. It equips the T cells with an enzyme that allows them to make their own supply of aspartate, a critical amino acid they are starved of inside these tumors.

Both tumor and healthy cells alike need aspartate, but within these toxic tumors, T cells are outcompeted by cancer cells for the raw material both need to make it. By engineering an aspartate-making enzyme into their T cells, the researchers hope to give them the extra oomph needed to survive. If they stay alive, these T cells may have a fighting chance against a cancer known to researchers as the beast of all beasts.

Drs.Irv Bernsteinand Suzanne Furuyama are studying whether they can reverse the ability of solid tumors to evade immunotherapy. Their focus is on the tumor microenvironment, where a tug-of-war is underway for control of the bodys immune response. Key to winning is to turn on an intercellular signaling system called Notch, which shifts the balance of immune cells from a tumor-protective to an anti-tumor state.

But simply flipping the Notch switch on can set inflammation loose against healthy cells as well. Bernsteins team has engineered a switch-flipper that recognizes both tumor cells and Notch to ramp up the inflammatory response of immune cells only in the right places. Their project will involve studies in mice to determine if the Notch-induced, anti-tumor immune cell state enhances solid tumor susceptibility to immunotherapies.

Drs. Justin Taylor and Jim Boonyaratanakornkit are developing a laboratory-designed antibody, a type of immune protein, capable of blocking four different respiratory viruses. Each of these common viruses poses a significant threat to the lives of cancer patients recovering from blood stem cell transplants. The four targeted viruses respiratory syncytial virus, human metapneumovirus, and two common strains of human parainfluenzavirus are among the deadliest for these patients and afflict vulnerable children and the elderly as well. Previously, the Taylor Lab has been able to isolate antibodies capable of protecting against at least two such viruses at the same time. The aim of this project is to engineer and test in animal models an antibody that can neutralize all four targeted viruses, leading to a new type of drug capable of saving thousands of lives each year.

Drs. Jarrod Dudakov and Sinad Kinsella study age-related decline of the thymus, the gland responsible for generating the diverse selection of T-cell receptors needed for a successful response to vaccines or pathogens. In their search for ways to stimulate regeneration of the thymus, they have identified two proteins, known as FOXN1 and DLL4, that are critical to regenerating thymus cells. The goal of their pilot project is to create a screening test for molecules that drive production of either of those proteins. Such protein-inducing molecules might serve as the basis for new clinical approaches that boost T- cell reconstitution. They could help restore immune function in transplant recipients as well as in patients whose thymus glands have been decimated by age, infection or chemotherapies.

Dr. Stephen Tapscott has joined with Dr. Robert Bradley, holder of the McIlwain Family Endowed Chair in Data Science, on a pilot project to explore the therapeutic potential of their discoveries of one way tumors may evade destruction by our immune system. Their focus is on a protein called DUX4, which may be used by a developing embryo and fetus to shield its cells from a mothers immune system. Shut down during childhood, the DUX4 gene is reawakened by some tumor cells, which use the ensuing shower of DUX4 proteins as an invisibility cloak against assault by cancer-attacking T cells. The researchers will develop an inventory of tumor cells that ramp up production of DUX4, explore what mutations enable this reawakening and establish strategies to disrupt it.

Drs. Ming Yu and William Grady are developing a highly sensitive test for early detection of both a deadly form of esophageal cancer and a precursor condition of abnormal cell growth known as high grade dysplasia, or HGD. Their testing panel, which picks up three distinctive genetic markers in patient specimens, has been shown to detect either HGD or the cancer esophageal adenocarcinoma in samples from biopsies or endoscopies. However, those procedures are invasive and expensive.

The pilot project aims to validate their test panel for use in a low-cost device that probes the esophagus with a pill-sized balloon rather than an endoscope. A less-expensive early detection test is expected to reduce mortality from esophageal adenocarcinoma, which is diagnosed in nearly 20,000 Americans each year.

Note:Scientists at Fred Hutch played a role in developing these discoveries, and Fred Hutch and certain of its scientists may benefit financially from this work in the future

More:
Fred Hutch Evergreen Fund awards six grants to promising projects - Fred Hutch News Service

Global Stem Cell and Primary Cell Culture Medium Market Research (2015-2026): In-depth Assessment of the Growth and other Aspects – Internet Shots

Stem Cells are a class of cells that have unlimited or immortal self-renewal ability, capable of producing at least one type of highly differentiated progeny cells. Primary Cells are cells that are cultured immediately after removal from the body. Stem Cell and Primary Cell Cultures are specialized systems, and as such developing and manufacturing media for these systems come with inherent complexities.

The global Stem Cell and Primary Cell Culture Medium market is valued at US$ xx million in 2020 is expected to reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2021-2026.

Access more details about this report at: https://www.themarketreports.com/report/global-stem-cell-and-primary-cell-culture-medium-market-research-report

(This is our latest offering and this report also analyzes the impact of COVID-19 on Stem Cell and Primary Cell Culture Medium market and updated by the current situation, especially the forecast)

The research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and also about each type from 2015 to 2026. This section mentions the volume of production by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better.

The major players in the market include Merck, STEMCELL Technologies, Irvinesci, Cell Applications, Inc, Biological Industries, Miltenyi Biotec, Swiss Medica Clinic, Promocell, Creative Biolabs, Lifeline Cell Technology, ScienCell Research Laboratories, Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix), etc.

Purchase this exclusive research report at: https://www.themarketreports.com/report/buy-now/1546660

Global Stem Cell and Primary Cell Culture Medium Market: Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the Stem Cell and Primary Cell Culture Medium market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Stem Cell and Primary Cell Culture Medium Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

Inquire for more details / sample / customization about this report at: https://www.themarketreports.com/report/ask-your-query/1546660

See more here:
Global Stem Cell and Primary Cell Culture Medium Market Research (2015-2026): In-depth Assessment of the Growth and other Aspects - Internet Shots

Cellular Therapy Products Market 2020 2025 analysis examined in new C – News by aeresearch

The report, titled Cellular Therapy Products Market, is a comprehensive document that provides valuable insights into market elements like drivers, restraints, competitive landscape, and technology evolution. For a better understanding of the market, the report offers a comprehensive analysis of the key segments and future growth prospects. The current COVID-19 pandemic has significantly changed market dynamics and the global economy. The report provides an impact analysis of the pandemic on the entire market. It also provides an analysis of the current and future impact. The report provides a comprehensive analysis of the dynamic changes in trends and requirements due to the COVID-19 pandemic. The report also includes a post-COVID scenario and prospects for future growth.

The research report on Cellular Therapy Products market encloses a complete examination of present and future scenario of this industry domain. It mentions the growth driving factors and opportunities which will help in industry expansion, as well as the challenges that will hamper the market growth.

The report offers historic as well as current data on various market segmentations to determine key products, applications, and end-users impacting the business revenue. It also highlights and market share and growth rate of the industry over the analysis period. Besides, the study contains pricing models and consumption patterns of this business space.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/308835

Questions about the regional terrain that are answered in the Cellular Therapy Products market report:

Other vital pointers in the Cellular Therapy Products market report:

Key Reasons to Purchase

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/308835

Read more from the original source:
Cellular Therapy Products Market 2020 2025 analysis examined in new C - News by aeresearch